Biologic therapy of breast cancer: Focus on co-inhibition of endocrine and angiogenesis pathways

Vivek Roy, Edith A. Perez

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

There remains a high unmet need for effective treatments for metastatic breast cancer. In recent years there have been many advances in the understanding of biological basis of cancer. Several cellular pathways have been identified that play crucial roles in causing or maintaining the cancer phenotype. Many new agents that target these pathways have entered the clinic or are being investigated. In order to improve the therapeutic efficacy seen with single-agent regimens, rational combinations of targeted agents are being evaluated in ongoing trials. The optimal sequencing and combination of agents has yet to be established. Endocrine and vascular endothelial growth factor pathways are the two most prominent pathways active in breast cancer cells and inhibition of either of these is associated with clinical benefit. Here we discuss the rationale for simultaneously targeting these pathways and highlight ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalBreast Cancer Research and Treatment
Volume116
Issue number1
DOIs
StatePublished - Jul 1 2009

Keywords

  • Angiogenesis
  • Aromatase inhibitor
  • Breast cancer
  • Clinical trial
  • Sorafenib
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Biologic therapy of breast cancer: Focus on co-inhibition of endocrine and angiogenesis pathways'. Together they form a unique fingerprint.

  • Cite this